Latest Cancer Drugs - OnCare Cancer Center Latest Cancer Drugs Intruduction
New Approved Drugs for Hematologic Malignancies and Solid Tumors:
The following are a listing of new agents approved by the U.S. FDA since 2010 and their indications. For some drugs, their indication may have expanded beyond their original registered indications over the years.
For further enquiry, please e-mail drug@oncare.com.hk or call (852) 3588-2400
(Last updated: 6th January, 2016)
Cancer Name |
FDA Approved Year |
Drugs Name |
|||
|
Lung Cancer |
|||||
|
EGFR T790M mutation positive |
2015 |
Osimertinib (Tagrisso) |
|||
|
Lung Cancer |
2015 |
Penbrolizumab (Keytruda) |
|||
|
Squamous cell lung cancer |
2015 |
Necitumumab (Portrazza) |
|||
|
Lung Cancer + ALK |
2015 |
Alectinib (Alecensa) |
|||
|
Squamous cell lung cancer |
2015 |
Opdivo (Nivolumab) |
|||
|
ALK + Non small cell Lung cancer |
2014 |
Zykadia (ceritinib) |
|||
|
EGFR mutation + lung cancer |
2013 |
Gilotrif (afatinib) |
|||
|
Lung Cancer |
2012 |
Abraxane (paclitaxel protein-bound) |
|||
|
ALK + Non small cell Lung cancer |
2011 |
Xalkori (crizotinib) |
|||
|
Colorectal Cancer |
|||||
|
Colorectal Cancer |
2015 |
1) Ramucirumab (Cyramza) |
|||
|
Colorectal Cancer |
2012 |
1) Zaltrap (ziv-aflibercept) |
|||
|
Breast Cancer |
|||||
|
ER +, HER 2 – Breast Cancer |
2015 |
Ibrance (palbociclib) |
|||
|
HER 2+ Breast Cancer |
2013 |
Kadcyla (ado-trastuzumab emtansine) |
|||
|
HER 2+ Breast Cancer |
2012 |
Perjeta (petuzumab) |
|||
|
Hormone receptor + Breast Cancer |
2012 |
Afinitor (everolimus) |
|||
|
Breast Cancer |
2010 |
Halaven (eribulin mesylate) |
|||
|
Prostate Cancer |
|||||
|
Castration resistant Prostate Cancer |
2012 |
Xtandi (enzalutamide) |
|||
|
Prostate Cancer |
2011 |
Zytiga (abiraterone acetate) |
|||
|
Hormone refractory Prostate Cancer |
2010 |
Provenge (sipuleucel-T) |
|||
|
Prostate Cancer |
2010 |
Jevtana (cabazitaxel) |
|||
|
Malignant Melanoma |
|||||
|
BRAF mutation positive |
2015 |
Cobimetinib (Cotellic) |
|||
|
Melanoma |
2014 |
1) Keytruda (pembrolizumab) |
|||
|
Stomach Cancer |
2014 |
Cyramza (ramucirumab) |
|||
|
BRAF + Melanoma |
2013 |
1) Tafinlar (dabrafenib) |
|||
|
BRAF + Melanoma |
2011 |
Zelboraf (vemurafenib) |
|||
|
Melanoma |
2011 |
Yervoy (ipilimumab) |
|||
|
Malignant Lymphoma |
|||||
| Hodgkin’s lymphoma | 2016 May | Opdivo (Nivolumab) (NEW) | |||
|
Lymphoma Waldenstrom’s Macroglobulinemia |
2015 |
Ibrutinib (Imbruvica) |
|||
|
Follicular B cell Lymphoma |
2014 |
Zydelig (idelalisib) |
|||
|
Peripheral T cell Lymphoma |
2014 |
Beleodaq (belinostat) |
|||
|
Mantle Cell Lymphoma |
2013 |
1) Revlimid (lenalidomide) |
|||
|
Hodgkin’s lymphoma |
2011 |
Adcetris (brentuximab vendotin) |
|||
|
Kidney Cancer |
|||||
| Kidney Cancer | 2016 May 2016 Apr |
Levima (Lenvatinib) (NEW) Cabometyx (Cabozantinib) (NEW) |
|||
|
Kidney Renal Cell cancer |
2015 |
Nivolumab (Opdivo) |
|||
|
Kidney Cancer |
2012 |
Inlyta (Axitinib) |
|||
| Bladder Cancer | |||||
|
Bladder Cancer |
2016 May |
Tecentriq (Otezolizumab) (NEW) |
|||
|
Skin Cancer |
|||||
|
Basal cell Carcinoma |
2012 |
Erivedge (vismodegib) |
|||
|
Pancreas Cancer |
|||||
|
Pancreas Cancer |
2015 |
Irinotecan Liposome Inj. (Onivyde) |
|||
|
Acute Leukemia |
|||||
|
Acute Lymphocytic Leukemia |
2014 |
Blincyto (blinatumomab) |
|||
|
Acute Lymphocytic Leukemia |
2012 |
Marqibo (vinCRIStine sulfate LIPOSOME injection) |
|||
|
Chronic Leukemia |
|||||
| Chronic Lymphocytic Leukemia | 2016 Apr | Venclexta (Venetoclax) (NEW) | |||
|
Chronic Lymphocytic Leukemia, Follicular B cell lymphoma, small lymphocytic lymphoma |
2014 |
Zydelig (idelalisib) |
|||
|
Chronic lymphocytic Leukemia |
2014 |
Imbruvica (ibrutinib) |
|||
|
Chronic lymphocytic Leukemia |
2013 |
Gazyva (oblintuzumab) |
|||
|
Chronic Myeloid Leukemia |
2012 |
Bosulif (bosutinib) |
|||
|
Chronic Myeloid Leukemia |
2012 |
Iclusig (ponatinib) |
|||
|
Chronic Myeloid Leukemia |
2012 |
Synribo (omacetaxine mepesuccinate) |
|||
|
Multiple Myeloma |
|||||
|
Multiple Myeloma |
2015 |
1) Elotuzumab (Empliciti) |
|||
|
Multiple Myeloma |
2013 |
1) Pomalyst (pomalidomide) |
|||
|
Multiple Myeloma |
2012 |
Kyprolis (carfizomib) |
|||
|
Ovary Cancer |
|||||
|
BRCA mutated Ovary Cancer |
2014 |
Lynparza (olaparib) |
|||
|
Thyroid Cancer |
|||||
|
Thyroid Cancer |
2015 |
Lenvatinib (Lenvima) |
|||
|
Medullary thyroid cancer |
2012 |
Cometriq (cabozantinib) |
|||
|
Thyroid Cancer |
2011 |
Vandetanib (vandetanib) |
|||
|
Sarcoma |
|||||
|
Soft Tissue Sarcoma |
2015 |
Trabectedin (Yondelis) |
|||
|
Soft Tissue Sarcoma |
2012 |
Votrient (pazopanib) |
|||
|
Neuroendocrine Tumor |
|||||
|
Pancreatic Neuroendocrine Tumor |
2011 |
Afinitor (everolimus) |
|||
|
Neuroblastoma |
|||||
|
Neuroblastoma |
2015 Mar |
Unituxin (Dinutuximab) (NEW) |
|||
|
Basal Cell Carcinoma |
|||||
|
Basal Cell Carcinoma |
2015 Jul |
Odomzo (Sonidegib) (NEW) |
|||
